Roth Capital affirms Ligand Pharma (Nasdaq: LGND) at Buy with a price target of $149 following Deutsche Bank's downgrade to ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Trader Talk

Deutsche Bank Downgrades Ligand Pharma (LGND) to SellAugust 5, 2016 6:45 AM Form 10-Q LIGAND PHARMACEUTICALS For: Jun 30August 4, 2016 4:24 PM Roth Capital Bumps PT on Ligand Pharma (LGND) up to $149; Says Running on All CylindersAugust 4, 2016 2:27 PM Form 8-K LIGAND PHARMACEUTICALS For: Aug 04August 4, 2016 9:07 AM Ligand Pharma (LGND) Tops Q2 EPS by 10c; Affirms FY16 OutlookAugust 4, 2016 8:56 AM